1Parente B, Barroso A, Conde S,et al.A prospective study of Gemcitabine and Carboplatin as first -line therapy in advanced non-small-cell lung cancer:toxicity of a three-versus a four-week schedule[J]. Semin Oncol,2001,28(3):10-14.
2Anderson H,Lund B,Bach F,et al.Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer. a phase II study[J].J Clin Oncol,1994,12(9):1821-1826.
3Baker CH, Banzon J, Bollinger JM, et al. 2'-Deoxy-2' methylenecytidine and 2'-deoxy-2' 2'-difluorocytidine 5'- diphosphates:potent meehanismbased inhibitors of ribonucleotide reductase[J].J Med Chem,1991,34(6):1879-1884.
4Ruiz van Haperen VW,Veerman G,Vermorken JB,et al.2'-Difluorodeoxycytidine incorporation into RNA and DNA of tumour cell lines[J].Biochem Pharmacol,1993,46(4):762-766.
3Faivre S,Le Chevalier T,Monnerat C,et al.PhaseⅠ-Ⅱand pharmacokinetic study of gemcitane combined with oxaliplatin in platents with advanced non-small-cell lung cancer and ovarian carcinoma[J].Ann Oncol,2002,13(9):1479.
